bitBiome, Inc., a start-up company from Waseda University in Japan, and National Cancer Center of Japan&n...
Japan headquartered Astellas Pharma Inc. and Audentes Therapeutics, Inc. have entered into a definitive agreement for As...
Chugai Pharmaceutical has announced that the "New England Journal of Medicine" (NEJM) online edition November 27 R...
Japan based Fujitsu Laboratories Ltd. and Aichi Cancer Center (ACC) have successfully concluded a comprehensive cooperat...
Japan based Ono Pharmaceutical Co., Ltd. has announced that ONO submitted an application of tirabrutinib hydrochloride (...
Intravenous Infusion Monotherapy Dosage and Schedule in Japan Ono Pharmaceutical Co., Ltd. has announced that ONO submit...
Hitachi, Ltd. headquartered in Tokyo, Japan, is focusing on Social Innovation Business combining its operational technol...
US based Ardelyx, Inc., a specialized biopharmaceutical company focused on developing first-in-class medicines to improv...
US based Woolsey Pharmaceuticals has announced that it has completed a license agreement with Japanese pharmaceutical co...
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., has announced the launch of Ella the Jellyfish, the first Amaz...
Japan based Shionogi & Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has approved FETROJA®...
Tokyo headquartered Eisai Co., Ltd. announced that it has launched the Equfina® 50mg TABLETS (safinamide mesila...
Japan headquartered Astellas Pharma Inc. and US based Welldoc, Inc. have entered into a collaboration and license agreem...
Merck, a leading science and technology company, has announced that the Japanese Ministry of Health, Labour and Welfare ...
Japan headquartered Toray Industries, Inc., has made an agreement with the Japan International Cooperation Agency (JICA)...
Sandoz has announced that it has entered into a binding agreement for the planned acquisition of the Japanese business o...
Indian pharma major Lupin Limited (including its subsidiaries, together referred to as ‘Lupin’) a...
Cancer Intelligence Care Systems, Inc. (CICS) and STELLA PHARMA CORPORATION will commence a Phase I clinical trial of Bo...
